Pharmalive - The Pulse of the Pharmaceutical Industry


Search Criteria: Search In:  
Conferences
  
ARCHIVE
1999 | 2000 | 2001 |
2002 | 2003 | 2004 |
2005 | 2006 | 2007 |
2008 | 2009 | 2010


Top 50 Pharmaceutical Companies Charts & Lists

Pharmaceutical Company of the Year
Roche
With six months remaining as chief executive of Roche, Franz Humer has led the company to record gains in 2006 and 2007 through organic growth.
By Steven Niles


21st Annual Report: Belt tightens on big pharma
The pharmaceutical industry is cutting costs as the pressure of weak pipelines, generic drugs, and product failures pummels major players.
By Christiane Truelove

Abbott: Abbott narrows focus
A run of prominent acquisitions and an attempted divestiture reflect continuing efforts to move toward higher-growth innovation and technology-driven business in emerging therapeutic areas.
By Joshua Slatko

AstraZeneca: Brennan wields the ax
Initiatives to build the pipeline and keep the company competitive ate into AstraZeneca’s profits in early 2007 and will cost jobs by 2010.
By Steven Niles

Bayer: New magnitude
Business improvements and expansion at Bayer have led to an advancement in operational profitability.
By Gina-Louise Monari

Biotech: On the growth track
The leaders of the biotechnology sector are generating record revenue and robust growth, but the industry is preparing for the challenges that will come with success.
By Gina-Louise Monari

Bristol-Myers Squibb: Adversity builds character
Bristol-Myers Squibb endured public embarrassment in 2006 due to the Plavix fiasco, but past troubles may be overshadowing future potential.
By Joshua Slatko

Eye care: Focus in opposite directions
The independent eye-care companies went in very different directions in 2006, with two industry leaders showing strong growth and another struggling against major financial and product setbacks.
By Joshua Slatko

Generics: Generics on a roll
Abundant patent expirations, major acquisitions, and impending biogenerics legislation are changing the face of the generics industry.
By Joshua Slatko

GlaxoSmithKline: Uncertainty remains
GlaxoSmithKline experienced solid growth in 2006, but 2007 has been defined by the divergent fates of Avandia and Alli.
By Steven Niles

Japan: Negative growth
Government restrictions and a push for generics has caused the Japanese market to post negative growth for the first time in six years.
By Steven Niles

Johnson & Johnson: Long-term strength with a cost
Cost-cutting measures at Johnson & Johnson will eliminate jobs, but executives expect their efforts to result in a more profitable company in the long run.
By Steven Niles

Lilly: Lilly’s roller coaster
A doubling of Cymbalta sales, an attack on Zyprexa in the New York Times, a major liability settlement, key victories in court, two pipeline setbacks, and continuing restructuring were part of Lilly’s roller-coaster 2006.
By Joshua Slatko

Merck & Co.: Out to launch
The market introduction of five new products in 2006 has validated Merck’s strategy of R&D efficiency as the company works past the loss of Vioxx.
By Joshua Slatko

Merck KGaA: Leap toward innovation
New management, the acquisition of Serono, and focused diversification are driving an era of change at Merck KGaA.
By Gina-Louise Monari

Novartis: Health care at the fore
Novartis is pushing forward in profitability as the company concentrates on pharmaceuticals and health care.
By Gina-Louise Monari

Pfizer: In need of repairs
Faced with a slump in performance, Pfizer leaders have set five immediate priorities designed to turn around the company’s fortunes.
By Steven Niles

Sanofi-Aventis: Competitive charge
Sanofi-Aventis is working through internal and external challenges and remains committed to sustainable development.
By Gina-Louise Monari

Schering-Plough: Sustaining momentum
Schering-Plough continues to pursue its successful Action Agenda, entering the Build the Base phase to extend core businesses into new markets.
By Gina-Louise Monari

Wyeth: Three pillars of wisdom
Striking a balance between small molecules, vaccines, and biotechnology, Wyeth continued a trend of double-digit bottom-line growth in 2006.
By Joshua Slatko 
 
Ask The Experts

MedAdNews
What are the main takeaways you had from the FDA hearings on social media ...
Asia is a rapidly growing market with deep traditional roots, so is this geographic ...
As I manage a community outreach program for a large hospital, I observe how ...

R&D Directions
Are there any ways to ameliorate the cardiac risks of a drug in development, if such ...
Do you see a discernable increase in demand for formulation development services ...
What are the one or two, in your opinion, most promising novel imaging techniques ...

Podcasts

The MedAdNews Show
Episode 1: Tax Terror
Download

Webcasts

MedAdNews
Promotional Effectiveness with the Physician, Pharmacy, and Patient
Wednesday, March 3, 2010 2PM – 3PM EST
Register

Views on Patient Adherence
Tuesday, January 12, 2010 2:00 PM EDT
View Webinar

Improving Compliance Through Master Data Management and an Aggregate Spend Solution
Monday, September 21, 2009 2:00 PM EDT
View Webinar

R&D Directions
Investigator Site Solutions for Clinical Trials
Thursday, September 17, 2009
View Webinar

Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook

This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.

The introductory rate of $395 expires February 17, 2010.

Learn More

about us | advertise | contact us | home
terms of use | privacy | copyright | site map 		©2010 Canon Communications Pharmaceutical Media Group